将患者与公众贡献者纳入临床试验独立数据监查委员会(IDMC)
英国南安普顿临床试验单元(SCTU)采用基于设计和行动研究的方法,开发并试点针对公众贡献者的培训项目,使其能参与独立数据监查委员会(IDMC)。在四项SCTU癌症试验中收集反馈并完善流程,结果显示培训有用且信息丰富,公众贡献者能对IDMC会议做出有意义的贡献,反馈总体积极,表明在提供充分培训与资源时纳入公众贡献者是可行的。
要点
- 公众贡献者极少参与独立数据监查委员会(IDMC),缺乏如何纳入及影响的证据。
- SCTU开发并试点培训项目,在四项癌症试验中收集反馈并完善。
- 反馈表明培训有用,公众贡献者能对IDMC会议做出有意义的贡献。
核心结论
- 项目开发、审查并完善了公众贡献者有意义参与IDMC所需的培训材料与资源。
- 来自公众贡献者、试验团队和IDMC主席的反馈总体积极,表明在提供充分培训与资源时纳入公众贡献者是可行的,能增强委员会工作并受到相关方欢迎。
- 已识别研究的局限性和未来工作,以进一步评估纳入公众贡献者对IDMC的影响。
研究设计与样本
- 采用基于设计和行动研究的方法,与SCTU的试验经理和统计师合作开发初始培训项目。
- 培训项目在一项SCTU癌症试验中试点,利用公众贡献者、试验人员、首席研究员和IDMC主席的反馈完善流程。
- 随后在另外三项SCTU试验中进一步评估,并通过参与者问卷再次收集反馈。
主要发现
- 培训对公众贡献者有用且信息丰富,使其能够对IDMC会议做出有意义的贡献。
- 建设性反馈帮助进一步完善流程,以便未来在SCTU试验中推广。
- 来自公众贡献者、试验团队和IDMC主席的反馈总体积极。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Patient and public involvement (PPI) is well established in clinical trials and trial oversight groups in the UK. But public contributors are rarely involved in Independent Data Monitoring Committees (IDMCs), meaning there is little or no evidence for how to include the public in these complex meetings or the impact PPI may have. As a Cancer Research UK core-funded clinical trials unit, the Southampton Clinical Trials Unit (SCTU) coordinates numerous phase II and III cancer drug trials with IDMCs. We aimed to establish a process to include PPI in these committees, but first needed to assess the feasibility of including public contributors and determine what training and resources they need to take part. Here we summarise our process of developing these training and resources to inform others who wish to include public contributors onto trial IDMCs. METHODS AND FINDINGS: We used design-based and action research methods to develop an initial training programme, working with trial managers and statisticians at the SCTU to ensure key elements of the IDMC process were covered and explained. This was piloted in a SCTU cancer trial, and feedback from the public contributor, trial staff, Chief Investigator and IDMC chair was used to refine the process. The programme was then further evaluated in three more SCTU trials, and feedback was again gathered through participant questionnaires. Our findings show that the training was useful and informative for public contributors, allowing them to contribute meaningfully to IDMC meetings, while constructive feedback allowed us to refine the process further for future roll-out across SCTU trials. CONCLUSIONS: The findings of this project allowed us to develop, review and refine the training materials and resources required for public contributors to meaningfully take part in IDMCs. Furthermore, feedback received from public contributors, trial teams and IDMC chairs was largely positive and suggests that the inclusion of public contributors, when adequate training and resources are provided, is feasible, can enhance the work of these committees and is welcomed by those involved. Limitations to the research and future work have been identified to further assess the impact of including public contributors in IDMCs.
引用
- Allaway E, Soulsby I, Keyworth N, et al. Including patient and public contributors on clinical trial Independent Data Monitoring Committees (IDMCs). Trials. 2026. PMID: 41703579. doi:10.1186/s13063-026-09559-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。